Literature DB >> 22192904

Results of fractional flow reserve measurement to evaluate nonculprit coronary artery stenoses in patients with acute coronary syndrome.

Ramón Lopez-Palop1, Pilar Carrillo, Francisco Torres, Iñigo Lozano, Araceli Frutos, Pablo Avanzas, Alberto Cordero, Juan Rondán.   

Abstract

INTRODUCTION AND
OBJECTIVES: Multivessel disease is usually present in almost half of patients with acute coronary syndromes. Angiography is insufficiently accurate to decide on coronary revascularization in moderate nonculprit lesions. There is some debate about the usefulness of fractional flow reserve assessed by intracoronary pressure wire in acute coronary syndromes. We studied the results of using fractional flow reserve values to decide whether to perform coronary revascularization of nonculprit angiographically moderate lesions in patients with acute coronary syndrome and multivessel disease.
METHODS: The fractional flow reserve was used to decide whether to revascularize angiographically moderate nonculprit lesions in a cohort of consecutive patients with acute coronary syndromes recruited in 2 centers.
RESULTS: One hundred and seven patients were included. Based on fractional flow reserve values, 81 patients (75.7%) were not revascularized. All lesions studied were revascularized in 26 patients (24.3%). Patient characteristics of the nontreated group and treated group were, respectively, diseased vessels, 1.3 (0.7) vs 1.4 (0.6) (P<.4); fractional flow reserve-studied lesions, 1.2 (0.5) vs 1.1 (0.4) (P=.3); stenosis, 46.1 (8.3)% vs 47.9 (10.3)% (P=.4); fractional flow reserve, 0.86 (0.1) vs 0.70 (0.1) (P<.005). After 1 year of follow-up, no significant differences in major cardiovascular events were observed between groups. There no deaths or nonfatal myocardial infarctions attributable to fractional flow reserve -deferred lesions. Coronary revascularization of the studied lesions was performed in 3 nontreated group patients (3.7%) due to disease progression.
CONCLUSIONS: Fractional flow reserve assessed by intracoronary pressure wire is useful in deciding whether to revascularize angiographically moderate nonculprit lesions in patients with acute coronary syndrome and multivessel disease.
Copyright © 2011 Sociedad Española de Cardiología. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22192904     DOI: 10.1016/j.recesp.2011.09.020

Source DB:  PubMed          Journal:  Rev Esp Cardiol (Engl Ed)        ISSN: 1885-5857


  6 in total

1.  Performing and Interpreting Fractional Flow Reserve Measurements in Clinical Practice: An Expert Consensus Document.

Authors:  Stephan Achenbach; Tanja Rudolph; Johannes Rieber; Holger Eggebrecht; Gert Richardt; Thomas Schmitz; Nikos Werner; Florian Boenner; Helge Möllmann
Journal:  Interv Cardiol       Date:  2017-09

2.  Rapid progression of nonculprit coronary lesions six weeks after successful primary PCI in culprit artery: a case report.

Authors:  Jianjin Tang; Zemu Wang; Dingguo Zhang; Liansheng Wang
Journal:  J Biomed Res       Date:  2014-03-15

Review 3.  Fractional flow reserve in acute coronary syndromes: A review.

Authors:  Nikunj R Shah; Rasha Al-Lamee; Justin Davies
Journal:  Int J Cardiol Heart Vasc       Date:  2014-11-11

Review 4.  Virtual (Computed) Fractional Flow Reserve: Future Role in Acute Coronary Syndromes.

Authors:  Hazel Arfah Haley; Mina Ghobrial; Paul D Morris; Rebecca Gosling; Gareth Williams; Mark T Mills; Tom Newman; Vignesh Rammohan; Giulia Pederzani; Patricia V Lawford; Rodney Hose; Julian P Gunn
Journal:  Front Cardiovasc Med       Date:  2021-10-22

Review 5.  Evaluation of intermediate coronary stenoses in acute coronary syndromes using pressure guidewire.

Authors:  Giampaolo Niccoli; Ciro Indolfi; Justin E Davies
Journal:  Open Heart       Date:  2017-06-14

6.  Fractional Flow Reserve-Guided Strategy in Acute Coronary Syndrome. A Systematic Review and Meta-Analysis.

Authors:  José Luís Martins; Vera Afreixo; José Santos; Lino Gonçalves
Journal:  Arq Bras Cardiol       Date:  2018-09-21       Impact factor: 2.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.